In 2020, BioNTech CEO Ugur Sahin proudly announced, "...we chose lipid nanoparticles that promote migration from the muscle cells into the lymph nodes."

Source:  "DIE PRESS", 9-02-2020, translated from German to English. - https://tinyurl.com/2p8tscmx

"Depending on how these lipid nanoparticles are constructed on the surface, they behave differently. Sahin: "For the Covid-19 candidate vaccine, we chose lipid nanoparticles that promote migration from the muscle cells into the lymph nodes. Dendritic (antigen-presenting; note) cells then present the resulting S-protein to the immune system. We have in According to the early data published so far, both a strong antibody reaction of the B cells and the development of specific CD4-positive and CD8-positive T cells were observed.The CD4 cells promote a protective immune response, the CD8 cells remain in the blood for a long time and inhibit the replication of the virus in infected cells."

https://tinyurl.com/2p8tscmx

WIKI:  "In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy." - https://en.wikipedia.org/wiki/BioNTech

Whistleblower, Prof. Ulrike Kammerer - Coronona Investigative Committee
BioNTech CEO Ugur Sahin admits deliberate selection of Lipid Nanoparticles that do not remain at the injection site in the arm but migrate to the lymph nodes.

"For the Covid-19 candidate vaccine, we chose lipid nanoparticles that promote migration from the muscle cells into the lymph nodes." - BioNTech CEO Ugur Sahin

Prof. Ulrike Kammerer Deposition

https://odysee.com/@Corona-Investigative-Committee:5/session-82-en:1?r=8cSGjqEoyncQGynLZgG9WAbC61LaBPpT&t=15906
https://tinyurl.com/4n63r5n9